Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2024-06-27 AGM Information
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox : Assemblée Générale Ordinaire 2024
AGM Information Classification · 1% confidence The document is titled "Communiqué de presse" and explicitly discusses the "Assemblée Générale Ordinaire 2024" (Annual General Meeting 2024). It details the failure to meet quorum on the first call and sets a new date for the second call (July 15, 2024). This content directly relates to the scheduling and proceedings of the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (4993 chars) is substantial enough to be the primary communication, not just a brief announcement of a report (RPA/RNS).
2024-06-27 French
Nicox: 2024 Ordinary Shareholder Meeting
AGM Information Classification · 1% confidence The document is explicitly titled "Press Release" and concerns the rescheduling of the "2024 Ordinary Shareholder Meeting" from June 28 to July 15. It details the agenda, quorum issues, and how shareholders can vote. This content directly relates to the logistics and announcement of the Annual General Meeting (AGM). Therefore, the most appropriate classification is AGM Information (AGM-R). Although it is a press release, its specific subject matter overrides the general 'RPA' or 'RNS' categories.
2024-06-27 English
Nicox annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription sous forme d’ABSA d’un montant total de 3,3 millions d’euros et étend son horizon de trésorer
Share Issue/Capital Change Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and details the success of a capital increase ('augmentation de capital') involving the issuance of new shares and warrants (ABSA). It explicitly mentions the gross proceeds (€3.3 million), the extension of the cash runway, and changes in shareholding structure. This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document is a full announcement, not just a notice of publication (RPA/RNS), and its length (23,772 chars) confirms it is the primary report.
2024-06-19 French
Nombre de droits de vote au 31 mai 2024
Share Issue/Capital Change Classification · 1% confidence The document is titled "PUBLICATION MENSUELLE DU NOMBRE D'ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE" (Monthly publication of the number of shares comprising the capital and the total number of voting rights) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of May 31, 2024. This type of regular, mandatory disclosure regarding share capital and voting rights is a specific regulatory filing, but it does not fit neatly into the primary categories like 10-K, IR, or ER. Since it is a specific regulatory disclosure that doesn't match the other defined codes (like DIRS, DIV, SHA, etc.), the most appropriate fallback category is Regulatory Filings (RNS), as it represents a general regulatory announcement required by the market authority (AMF). The document length (3170 chars) is short, but it is the report itself, not an announcement *of* a report, so RPA is less appropriate than RNS for this specific type of mandatory capital structure disclosure.
2024-06-03 French
Number of voting rights as of May 31, 2024
Share Issue/Capital Change Classification · 1% confidence The document is titled "MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS" and explicitly references Article 223-16 of the AMF (Autorité des marchés financiers) General Regulation. It provides a specific snapshot date (May 31, 2024) for the total number of shares and voting rights. This type of regular, mandatory disclosure regarding the share structure and voting rights does not fit neatly into the primary financial reports (10-K, IR, ER) or corporate actions (DIV, SHA, POS). It is a specific regulatory disclosure concerning ownership structure. While it relates to capital, it is a recurring monthly update on the share count, not a financing event (CAP) or a general share issue (SHA). Given the options, this specific, recurring regulatory disclosure about the composition of capital and voting rights is best categorized as a general Regulatory Filing (RNS), as it is a mandatory, periodic regulatory update that doesn't match the more specific financial or corporate event codes. It is not a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ), which focus on specific transactions or ownership thresholds, but rather a comprehensive monthly count.
2024-06-03 English
Nicox annonce l’organisation d’un webcast pour ses actionnaires le 6 juin 2024 à 18h00 CET à l’occasion de son augmentation du capital déjà en cours
Report Publication Announcement Classification · 1% confidence The document is a press release dated May 31, 2024, announcing that Nicox will host a webcast on June 6, 2024, regarding its ongoing capital increase (augmentation du capital avec droits préférentiel de souscription). The core subject is the announcement of an event (webcast) related to a financing activity (capital increase). This strongly aligns with the 'Capital/Financing Update' category (CAP). Although it announces an event related to capital change, it is not the formal filing of the capital change itself (SHA) or a general regulatory announcement (RNS). Since it is specifically about fundraising/financing activities, CAP is the most precise fit. The document length is substantial (9582 chars), so it is not a simple RPA.
2024-05-31 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.